A Real-world Study of Patient and Physician Satisfaction With Repeated AbobotulinumtoxinA Treatment of Glabellar Lines in Chinese Patients

Background AbobotulinumtoxinA (aboBoNT-A; Dysport®) is approved in China for treating glabellar lines (GLs) with fast onset of action (median: 2 days) and effectiveness up to 6 months (Chinese pivotal trial data), but real-world data remain limited. Objectives Primary objective: to assess patient satisfaction following three cycles of aboBoNT-A treatment for moderate-to-severe GLs in a real-world setting. Secondary variables included effectiveness, patient and physician satisfaction in each cycle, and injection practice details. Methods In this non-interventional, multicenter study conducted in China, participants received 3 injection cycles of aboBoNT-A in the GL area, 3-6 months apart, with follow-up at Week 3, before the next treatment, and at end-of-study. Assessments included satisfaction questionnaires, GL wrinkle severity, and safety. Results At 3 weeks after the third injection, 100% of patients (N=204) were satisfied with treatment (very satisfied: 71.1%; satisfied: 28.9%, primary endpoint) and physicians were very satisfied/satisfied with overall treatment outcome in 99.5% of patients. Physicians reported ≥1-grade improvement in GL severity at maximum frown in ≥90% of patients at 3 weeks in each cycle and in ≥64% at ∼5 months post-treatment (at next treatment). For ≥99% of patients, physicians would recommend aboBoNT-A to colleagues. The treatment was well tolerated, with no new safety findings. Conclusions All patients were satisfied with aboBoNT-A GL treatment after 3 injection cycles in this Chinese real-world study. As supported by multiple outcome measures, both patients and physicians reported high satisfaction with treatment and long-lasting improvement in wrinkle severity across single- or repeat cycles. Treatment was well tolerated.